Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5204576 | 0.79 | TSHR (0.44) | RIPK2ALDH1A1POLBSIRT3TDP1 | |
| SCHEMBL174225 | 0.78 | RIPK2 (0.51) | RIPK2ALDH1A1POLBSIRT3TDP1 | |
| SCHEMBL6397435 | 0.78 | SMN1; SMN2 (0.49) | RIPK2ALDH1A1POLBSIRT3TDP1 | |
| SCHEMBL9196622 | 0.77 | CYP1A2 (0.43) | ALDH1A1TSHRSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL1992512 | 0.76 | RIPK2 (0.39) | RIPK2ALDH1A1POLBSIRT3TDP1 | |
| SCHEMBL1458362 | 0.74 | RIPK2 (0.41) | RIPK2ALDH1A1POLBSIRT3TDP1 | |
| SCHEMBL26404933 | 0.73 | NNMT (0.45) | RIPK2ALDH1A1POLBSIRT3TDP1 | |
| SCHEMBL15998476 | 0.73 | ALDH1A1 (0.46) | RIPK2ALDH1A1POLBSIRT3TDP1 | |
| SCHEMBL8986609 | 0.73 | RAB9A (0.48) | ALDH1A1TSHRSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL353368 | 0.72 | POLB (0.41) | RIPK2ALDH1A1POLBSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3164406-B1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA INC (US) | 2024-12-25 | — | — | EP | disclosed |
| US-10206937-B2 | Boronic acid derivatives and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170136047-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| EP-3164406-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | Rempex Pharmaceuticals, Inc. (US) | 2017-05-10 | — | — | EP | disclosed |
| WO-2016003929-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS, INC. (US) | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10206937-B2 | Boronic acid derivatives and therapeutic uses thereof | BCL6B, BTD, BCL6 | RIPK2 3333/4885ALDH1A1 1999/4885POLB 1563/4885 |
| US-20170136047-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | BCL6B, BTD, BCL6 | RIPK2 3333/4885ALDH1A1 1999/4885POLB 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.